Examination of pituitary adenylate cyclase-activating polypeptide in Parkinson’s disease focusing on correlations with motor symptoms

Pham, Dániel; Polgar, Beata; Tóth, Tünde; Jungling, Adel; Kovács, Norbert; Bíró, István; Pál, Endre; Szabò, D. G.; Fülöp, B; Reglődi, Dóra; Szántó, Zalán; Herczeg, Róbert; Gyenesei, Attila; Tamás, Andrea

doi:10.1007/s11357-022-00530-6

Cited by 11 publications

(7 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the significant correlation between PACAP levels and age has not been described in either healthy or patient populations, recently, our research group demonstrated significantly lower PACAP levels in a population of Parkinson’s disease patients older than 50 years. In this case, however, an increase in younger patients due to deep brain stimulation could not be excluded [ 17 , 20 ]. Thus, our study is currently the first in clinical research to demonstrate a significant decrease in the plasma PACAP levels in correlation with the age of the MM patients.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, significant alterations of this peptide have been detected in human tissues under various physiological and pathological conditions (e.g., neurological disorders: Parkinson’s disease, posttraumatic stress disorder; cardiac disorders: cardiomyopathies, acute myocardial infarction; kidney disorders: nephrotic syndrome, nephrectomy), in addition to various malignant disorders. These results suggest a potential role of PACAP in the diagnosis, prognosis, and clinical therapy of certain diseases [ 11 , 20 , 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and Prognostic Value of PACAP in Multiple Myeloma

Tóth

Alizadeh

Polgar

et al. 2023

IJMS

View full text Add to dashboard Cite

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a multifunctional neuropeptide with well-known anti-inflammatory, antioxidant, antitumor, and immunomodulatory effects. PACAP regulates the production of various proinflammatory factors and may influence the complex cytokine network of the bone marrow microenvironment altered by plasma cells, affecting the progression of multiple myeloma (MM) and the development of end-organ damage. The aim of our study was to investigate the changes in PACAP-38 levels in patients with MM to explore its value as a potential biomarker in this disease. We compared the plasma PACAP-38 levels of MM patients with healthy individuals by ELISA method and examined its relationship with various MM-related clinical and laboratory parameters. Lower PACAP-38 levels were measured in MM patients compared with the healthy controls, however, this difference vanished if the patient achieved any response better than partial response. In addition, lower peptide levels were found in elderly patients. Significantly higher PACAP-38 levels were seen in patients with lower stage, lower plasma cell infiltration in bone marrow, lower markers of tumor burden in serum, lower total urinary and Bence-Jones protein levels, and in patients after lenalidomide therapy. Higher PACAP-38 levels in newly diagnosed MM patients predicted longer survival and a higher probability of complete response to treatment. Our findings confirm the hypothesis that PACAP plays an important role in the pathomechanism of MM. Furthermore, our results suggest that PACAP might be used as a valuable, non-invasive, complementary biomarker in diagnosis, and may be utilized for prognosis prediction and response monitoring.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnostic and Prognostic Value of PACAP in Multiple Myeloma

Tóth

Alizadeh

Polgar

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Significant elevation of PACAP levels was observed in the most severe stage of Epworth sleepiness scale, measuring the severity of sleep disturbances. In PD patients older than 50 years at the time of diagnosis significantly lower PACAP levels were found compared to those who were younger, although patients without DBS treatment were older compared to DBS–treated patients ( 34 ). Interestingly, a similar age–related finding, as a transition decade, was described in case of human choroid plexus (CP) aging, which confirmed the results of previous in vivo experiments in which altered CP transcriptome was detectable in various central nervous system disorders ( 35 ).…”

Section: Neurological and Psychiatric Diseasesmentioning

confidence: 99%

Role of endocrine PACAP in age-related diseases

et al. 2023

Self Cite

View full text Add to dashboard Cite

Pituitary adenylate cyclase activating polypeptide (PACAP) is a conserved neuropeptide, which confers diverse anti-aging endocrine and paracrine/autocrine effects, including anti-apoptotic, anti-inflammatory and antioxidant action. The results of the in vivo and in vitro experiments show that increasing emphasis is being placed on the diagnostic/prognostic biomarker potential of this neuropeptide in a wide array of age-related diseases. After the initial findings regarding the presence and alteration of PACAP in different body fluids in physiological processes, an increasing number of studies have focused on the changes of its levels in various pathological conditions associated with advanced aging. Until 2016 – when the results of previous human studies were reviewed – a vast majority of the studies had dealt with age-related neurological diseases, like cerebrovascular and neurodegenerative diseases, multiple sclerosis, as well as some other common diseases in elderly such as migraine, traumatic brain injury and post-traumatic stress disorder, chronic hepatitis and nephrotic syndrome. The aim of this review is to summarize the old and the new results and highlight those ‘classical’ and emerging clinical fields in which PACAP may become subject to further investigation as a diagnostic and/or prognostic biomarker in age-related diseases.

show abstract

“…The brain-gut peptides related to the pathogenesis and treatment of PD mainly include GLP-1, ghrelin, nesfatin-1, and pituitary adenylate cyclase-activating polypeptide (PACAP) ( Dong et al, 2019 ). Serum levels of them show varying degrees of reduction in PD patients ( Song et al, 2017 ; Emir et al, 2019 ; Pham et al, 2022 ).…”

Section: Gut-brain Axis Pathogenesismentioning

confidence: 99%

Update to the Treatment of Parkinson’s Disease Based on the Gut-Brain Axis Mechanism

et al. 2022

View full text Add to dashboard Cite

Gastrointestinal (GI) symptoms represented by constipation were significant non-motor symptoms of Parkinson’s disease (PD) and were considered early manifestations and aggravating factors of the disease. This paper reviewed the research progress of the mechanism of the gut-brain axis (GBA) in PD and discussed the roles of α-synuclein, gut microbiota, immune inflammation, neuroendocrine, mitochondrial autophagy, and environmental toxins in the mechanism of the GBA in PD. Treatment of PD based on the GBA theory has also been discussed, including (1) dietary therapy, such as probiotics, vitamin therapy, Mediterranean diet, and low-calorie diet, (2) exercise therapy, (3) drug therapy, including antibiotics; GI peptides; GI motility agents, and (4) fecal flora transplantation can improve the flora. (5) Vagotomy and appendectomy were associated but not recommended.

show abstract

Examination of pituitary adenylate cyclase-activating polypeptide in Parkinson’s disease focusing on correlations with motor symptoms

Cited by 11 publications

References 101 publications

Diagnostic and Prognostic Value of PACAP in Multiple Myeloma

Diagnostic and Prognostic Value of PACAP in Multiple Myeloma

Role of endocrine PACAP in age-related diseases

Update to the Treatment of Parkinson’s Disease Based on the Gut-Brain Axis Mechanism

Contact Info

Product

Resources

About